Core Insights - 麦澜德 is focusing on the development and commercialization of non-invasive brain-computer interface (BCI) technology, integrating it with existing technologies and clinical scenarios [1] Group 1: Clinical Directions and Technology Development - The company has developed a closed-loop system for cognitive function intervention, which includes four modules: emotional recognition, emotional interaction, cognitive assessment, and cognitive intervention, currently in multi-center clinical validation [2] - In the field of motor function rehabilitation, 麦澜德 has innovatively combined soft exoskeleton hand functions with EEG devices to create a brain-machine hand training system, showing preliminary effectiveness superior to traditional interventions [2] - For mental and psychosomatic disease regulation, the company is developing a multi-modal brain physiological signal monitoring platform in collaboration with Zhejiang University and other institutions, aiming to create portable products for monitoring brain states [2] Group 2: Technical Advantages and Ecosystem - 麦澜德's core advantages lie in three areas: multi-modal BCI technology for precise screening and personalized treatment, central-peripheral closed-loop technology with early multi-center clinical trials, and breakthroughs in cognitive impairment and emotional interaction [3] - The company has established a collaborative ecosystem involving universities, hospitals, and enterprises, ensuring that research and development align with clinical needs and facilitating resource sharing [3] Group 3: Market Promotion and Competitive Landscape - 麦澜德 has initiated preliminary cooperation with several hospitals in Jiangsu Province and southwestern regions, with some devices already in use at leading hospitals [4] - The competitive landscape in the BCI field is dominated by non-invasive companies, where the speed of obtaining registration certificates and market promotion capabilities are key factors [4] - The company aims to maintain its competitive edge by focusing on core technology research and clinical transformation [4]

（文章来源：证券日报） 证券日报网讯麦澜德11月24日在互动平台回答投资者提问时表示，为保证所有投资者平等获悉公司信 息，根据信息披露公平原则，公司会在定期报告中披露报告期末的股东人数，敬请关注公司定期报告。 ...

公司公告汇总：麦澜德2025年前三季度拟派发现金红利29,342,357.10元（含税），每股派0.3元。 公司公告汇总：本次权益分派以扣除回购股份后的97,807,857股为基数，不进行公积金转增及送红 股。 股本股东变化：截至核查日，公司已累计回购2,192,143股，占总股本2.19%，回购股份不参与分 红。 南京证券就麦澜德差异化权益分派事项出具核查意见，确认公司已累计回购2,192,143股，占总股本 2.19%。依据规定，回购股份不参与利润分配。本次利润分配以97,807,857股为基数，每10股派3.00元 （含税），合计拟派发29,342,357.10元。差异化分派对除权除息参考价影响小于1%。保荐机构认为该 事项合规，未损害股东利益。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月21日收盘，麦澜德（688273）报收于34.31元，较上周的37.3元下跌8.02%。本周，麦澜 德11月17日盘中最高价报37.51元。11月21日盘中最低价报33.81元。麦澜德当前最新总市值34.31亿元， ...

Dividend Announcements - Jinlu Electronics announced a cash dividend of 0.1483572 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [1] - Deshi Co. declared a cash dividend of 1.40 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [1] - Shanghai Kaibao will distribute a cash dividend of 0.30 CNY for every 10 shares (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [1] Additional Dividend Announcements - Shichang Co. announced a cash dividend of 5.80 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [2] - Mylande declared a cash dividend of 0.30 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [2] - Zhiyang Innovation announced a cash dividend of 0.10 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [2] Further Dividend Announcements - Shentong Technology declared a cash dividend of 0.027 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [3] - Jinshi Resources announced a cash dividend of 0.07 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [3] - Gibit declared a cash dividend of 6.00 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [3] Final Dividend Announcements - Puris announced a cash dividend of 0.68 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [4] - Kaipu Testing declared a cash dividend of 2.00 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [4]

证券代码：688273 证券简称：麦澜德 公告编号：2025-048 南京麦澜德医疗科技股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 ■ 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025年11月7日的2025年第三次临时股东会审议通过。 二、分配方案 1.发放年度：2025年前三季度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东（南京麦澜德医疗科技股份有限公司回购专用证 券账户除外）。 根据中国证监会《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等有关规定，公司回购专用账户中的股份，不享有股东会表决权、利润分配、公积金转增股本、认 购新股和可转换公司债券等权利、不得质押和出借。 重要内容提示： 每股现金红利0.3元（含税） ● 相关日期 公司根据上海证券交易所的相关规定，按照以下公式计算除权除息开盘参考价： 除 ...

证券日报网讯 11月20日晚间，麦澜德发布公告称，2025年前三季度利润分配方案为每股现金红利0.3元 （含税），股权登记日为2025年11月26日，除权（息）日及现金红利发放日均为2025年11月27日。 （文章来源：证券日报） ...

南京证券股份有限公司（以下简称"保荐机构"）作为南京麦澜德医疗科技 股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票并上市及持 续督导的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，对 麦澜德 2025 年前三季度利润分配所涉及的差异化权益分派事项进行了核查，发 表如下意见： 一、本次差异化权益分派的原因 公司于 2023 年 8 月 22 日召开第一届董事会第二十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司通过集中竞价交易 方式回购公司已发行的人民币普通股（A 股），回购股份的资金总额不低于人民 币 2,000 万元（含），不超过人民币 4,000 万元（含），回购股份的价格不超过 人民币 50 元/股（含），回购股份的期限自董事会审议通过本次回购股份方案之 日起 12 个月内。公司于 2024 年 5 月 31 日完成此次回购，本次累计回购股份 1,110,000 股，回购金额合计 3,220.5070 万元。 公司于 2024 年 7 月 1 日召开第二届董事会第八次 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-048 南京麦澜德医疗科技股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/11/26 | 2025/11/27 | 2025/11/27 | 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 11 月 7 日的2025年第三次临时股东会审议通 过。 二、分配方案 1. 发放年度：2025年前三季度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（南 京麦澜德医疗科技股份有限公司回购专用证券账户除外）。 根据中国证监会《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等有关规定，公司回购专用账户中的股份，不享有 股东会表决权 ...

麦澜德公告称，截至核查意见出具日，公司累计回购股份219.21万股，占总股本2.19%。公司2025年度 拟以实施权益分派股权登记日登记的总股本扣除回购专用证券账户股份数为基数分配利润，向全体股东 每10股派发现金红利3元（含税）。截至2025年10月23日，参与分红股份总数9780.79万股，拟派发现金 红利2934.24万元（含税），不进行公积金转增股本和送红股。保荐机构认为，本次分派符合规定，未 损害公司和股东利益。 ...

Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]